POSTED BY PULMONARY FIBROSIS FOUNDATION ON 5/20/2010
First In Vivo Proof-of-Concept Showing Impact of a Telomerase Activator in a Model of Human Disease
May 19, 2010-- Geron Corporation announced positive data on its orally available small molecule telomerase activator, TAT153, in an animal model of idiopathic pulmonary fibrosis (IPF). The data show that administration of TAT153 increased telomerase activity in the lung tissue, reduced inflammation, preserved functional lung tissue, slowed disease progression and attenuated loss of pulmonary function.
MEDICAL NEWS
ON 5/19/2010
New Orleans - According to researchers in Japan, inhaled N-acetylcysteine (NAC) monotherapy preserves more lung function in some idiopathic pulmonary fibrosis (IPF) patients than no therapy.
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 5/18/2010
NEW YORK (Dow Jones)--Pfizer Inc's (PFE) Revatio, which is identical to Viagra but in different dosage, missed the main goal of a study in an advanced form of a fatal lung disease, although improvements in some symptoms may aid patients that currently have no options.
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 5/18/2010
Lung Function and Survival Improved in Model of Radiation-induced Lung Fibrosis
FibroGen Pursues Human Trials in Fibrosis and Pancreatic Cancer
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 5/17/2010
NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan-drug designation for IL13-PE38QQR (IL13-PE) for the treatment of IPF.
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 5/17/2010
We realize many in the IPF community are disappointed at the FDA for not approving pirfenidone. It is somewhat unusual for the FDA to deny approval when the Advisory Board recommends approval (as it did in this case 9-3). It seems that the FDA may have been concerned that one of the trials did not demonstrate statistically significant benefit and therefore requested further studies be performed.
ADVOCACY
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 5/17/2010
Dear Pulmonary Fibrosis Community,
As the House of Representatives nears its holiday recess we are requesting everyone to contact his or her congressman or woman to ask them to sign on as a Co-Sponsor of H.R. 1079.IH, The Pulmonary Fibrosis Research Enhancement Act.
MEDICAL NEWS
ON 5/4/2010
NEW YORK, May 4 (Reuters) - InterMune Inc said U.S.
